Novartis CEO says he won't sell Sandoz unit

诺华CEO表示不会出售旗下仿制药单元山德士,此前传言四起

2019-07-30 15:30:00 pharmamanufacturing

本文共344个字,阅读需1分钟

Novartis CEO Vas Narasimhan pledged in a published interview that the Swiss drugmaker will not sell its generics unit amid a revamp that has prompted rumors about offloading Sandoz. “We will make Sandoz autonomous within Novartis, so it’s more competitive. Our plan is to focus Sandoz and make it better in the long-term,” said the CEO to a German newspaper on Saturday. Earlier this year, Sandoz announced a two-stage strategic "transformation" plan, which came with 900 layoffs. This news was preceded by the announcement that Richard Francis will be stepping down as CEO of Sandoz as of March 31 2019. Sandoz, which had nearly $10 billion in sales last year, upgraded its full-year sales target on July 18, adding the possibility of low-single-digit percentage sales growth.
诺华( Novartis )首席执行长纳拉希姆( Vas Narasimhan )在一次公开采访中承诺,这家瑞士制药商将不会出售旗下的仿制药部门。此前,该公司进行了一次重组,引发了有关出售 Sandoz 的传言。 “我们将使 Sandoz 在诺华(Novartis)内部实现自主,因此更具竞争力。我们的计划是关注 Sandoz ,并使其在长期内变得更好,”首席执行官上周六在一家德国报纸上表示。 今年早些时候, Sandoz 宣布了一个两阶段战略“转型”计划,裁员900人。此前,理查德·弗朗西斯宣布将从2019年3月31日起辞去 Sandoz 的首席执行官一职。 Sandoz 去年的销售额接近100亿美元,该公司在7月18日上调了全年销售目标,增加了销售增长率可能低于个位数的可能性。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文